ILT, thanks that article was an eye opener. I hope you're right and that amarin has been discussing this option it certainly would provide for a brighter future for vascepa and share price.
ILT--yeah, that would be a very fair take. I'd also add Amarin has more room to bargain up supplier prices than generics, which your post touches on now that I'm re-reading it. Also, I'd add that generics are acting individually as far as we know regarding supplier negotiations...
ILT, hope you don't mind but I will forward the article you posted to Elisabeth and request she forward to jt and the bod. Let's see if her reply has a hint of possibility that Amarin is considering this approach.
News 
Market Data 
Discover 
